SOPHiA GENETICS SA — FY2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone Q4 filing; the supplied text does not provide clear Q4-only financial results. Financial statements are audited and prepared under IFRS as issued by the IASB, in U.S. dollars.
Business context
SOPHiA GENETICS is a Swiss healthcare software company. Its cloud-native SOPHiA DDM platform analyzes genomic and other health data for hospitals, laboratories and biopharmaceutical customers. The company reported more than 750 customers, 390 recurring platform customers, and over 1.2 million genomic profiles analyzed by year-end 2022. Its 2022 launch, SOPHiA CarePath, is intended to combine genomic, radiomic, clinical and biological data.
Financial and operating metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $47.6 million | $40.5 million | +18% |
| Gross profit / margin | $31.3 million / 66% | $25.2 million / 62% | Margin +4 percentage points |
| Operating loss | $87.8 million | $71.5 million | Loss widened $16.3 million |
| Net loss | $87.4 million | $73.7 million | Loss widened $13.8 million |
| Operating cash flow | $(70.1) million | $(57.9) million | Cash use increased |
| Cash and cash equivalents | $161.3 million | $193.0 million | Down $31.7 million |
| Term deposits | $17.3 million | $72.4 million | Down $55.1 million |
| Total liabilities | $43.7 million | $44.8 million | Down $1.1 million |
Revenue was concentrated in the platform: SOPHiA DDM Platform revenue was $45.7 million, up 16%; workflow equipment and services revenue was $1.9 million, up 91%. EMEA generated $34.9 million, about 73% of revenue. North America contributed $6.7 million. No single end customer represented more than 5% of revenue.
Platform analysis volume rose 9% to 264,294. Recurring platform customers increased to 390 from 382; average revenue per platform customer rose to $93,691 from $92,028. Net dollar retention declined to 102% from 142%, and LTV/CAC fell to 4.0x from 7.7x. Revenue churn was 4%, versus 3% in 2021.
Balance-sheet liquidity included $161.3 million of cash and cash equivalents plus $17.3 million of term deposits. Lease liabilities were $16.7 million; the company reported no outstanding borrowings at year-end. Cash declined by $29.7 million overall, after $42.0 million of cash provided by investing activities, mainly from term-deposit maturities. The company said existing cash and cash equivalents were expected to fund operations and capital expenditures for at least 12 months.
Material changes versus FY2021
- Revenue increased 18%, although management cited an approximately $5.9 million unfavorable foreign-exchange impact. Platform analysis volume and biopharma revenue increased.
- Gross margin improved from 62% to 66%, helped in part by a $1.0 million Microsoft hosting-cost credit.
- Research and development expense rose 33% to $35.4 million; general and administrative expense rose 34% to $55.8 million. Selling and marketing expense decreased 2% to $28.3 million.
- Net loss increased to $87.4 million from $73.7 million, and operating cash use rose to $70.1 million from $57.9 million.
- Cash and term deposits declined substantially from FY2021, when the IPO and related share sales had generated significant financing proceeds. FY2022 financing cash flow was a $1.6 million outflow.
Outlook, risks and unusual items
- Outlook: No specific revenue or earnings guidance is provided in the supplied filing text. Management expects continued losses while investing in R&D, sales and marketing, customer relationships and regulatory clearances; it may seek additional capital. It expects near-term cloud-computing and storage costs to pressure gross margin, while anticipating longer-term improvement as scale and cost efficiencies develop.
- Contract commitment: A Microsoft agreement signed November 1, 2022 commits the company to approximately $69.4 million in computing and hosting costs through October 31, 2027.
- Regulatory and commercial risks: U.S. products are labeled for research use only; IVD clearance or approval is not assured. Coverage and reimbursement, market adoption, customer and partner retention, competition, and successful expansion of the platform and CarePath remain uncertain.
- Technology and data risks: The company depends on cloud providers, including Microsoft Azure, and faces cybersecurity, privacy, service-interruption and cross-border data-transfer risks. It reported no past security incident with a material adverse effect, but cannot assure future prevention.
- Financial and tax risks: The company believes it was a PFIC for U.S. federal tax purposes in 2022, but states the determination is uncertain and may also apply in 2023. U.S. investors should consult tax advisers. The Swiss tax holiday expired at year-end 2022; the company expects a standard combined Swiss corporate tax rate of approximately 13.5% from 2023.
- Controls: Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2022. Three previously identified material weaknesses were reported as remediated. As an emerging growth company, the issuer did not include an auditor attestation on internal controls.
- Other: The filing reports no material contingent assets or liabilities and no material subsequent events. No dividend is proposed for FY2022, and the company does not expect to pay dividends in the foreseeable future.
Investor verification checklist
- Review the audited IFRS statements and notes for cash burn, cash and term-deposit balances, lease liabilities, and the assumptions supporting the stated 12-month liquidity outlook.
- Track revenue growth against analysis volume, customer expansion, foreign-exchange effects, and the significant decline in net dollar retention.
- Assess the economics and minimum-spend implications of the $69.4 million Microsoft commitment, together with cloud-cost trends and gross-margin progress.
- Verify execution, customer adoption and regulatory status for CarePath and any planned U.S. IVD offerings; distinguish RUO products from products authorized for diagnostic use.
- Monitor PFIC status and availability of the company’s annual information statement for U.S. investors, and review potential dilution from equity compensation or future capital raises.